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Summary
Background The effect of the COVID-19 pandemic on HIV outcomes in low-income and middle-income countries is 
poorly described. We aimed to measure the impact of the 2020 national COVID-19 lockdown on HIV testing and 
treatment in KwaZulu-Natal, South Africa, where 1·7 million people are living with HIV.
Methods In this interrupted time series analysis, we analysed anonymised programmatic data from 65 primary care 
clinics in KwaZulu-Natal province, South Africa. We included data from people testing for HIV, initiating antiretroviral 
therapy (ART), and collecting ART at participating clinics during the study period, with no age restrictions. We used 
descriptive statistics to summarise demographic and clinical data, and present crude summaries of the main 
outcomes of numbers of HIV tests per month, ART initiations per week, and ART collection visits per week, before 
and after the national lockdown that began on March 27, 2020. We used Poisson segmented regression models to 
estimate the immediate impact of the lockdown on these outcomes, as well as post-lockdown trends.
Findings Between Jan 1, 2018, and July 31, 2020, we recorded 1 315 439 HIV tests. Between Jan 1, 2018, and June 15, 2020, 
we recorded 71 142 ART initiations and 2 319 992 ART collection visits. We recorded a median of 41 926 HIV tests 
per month before lockdown (January, 2018, to March, 2020; IQR 37 838–51 069) and a median of 38 911 HIV tests per 
month after lockdown (April, 2020, to July, 2020; IQR 32 699–42 756). In the Poisson regression model, taking into 
account long-term trends, lockdown was associated with an estimated 47·6% decrease in HIV testing in April, 2020 
(incidence rate ratio [IRR] 0·524, 95% CI 0·446–0·615). ART initiations decreased from a median of 571 per week 
before lockdown (IQR 498–678), to 375 per week after lockdown (331–399), with an estimated 46·2% decrease in the 
Poisson regression model in the first week of lockdown (March 30, 2020, to April 5, 2020; IRR 0·538, 0·459–0·630). 
There was no marked change in the number of ART collection visits (median 18 519 visits per week before lockdown 
[IQR 17 074–19 922] vs 17 863 visits per week after lockdown [17 509–18 995]; estimated effect in the first week of 
lockdown IRR 0·932, 95% CI 0·794–1·093). As restrictions eased, HIV testing and ART initiations gradually 
improved towards pre-lockdown levels (slope change 1·183/month, 95% CI 1·113–1·256 for HIV testing; 1·156/month, 
1·085–1·230 for ART initiations).
Interpretation ART provision was generally maintained during the 2020 COVID-19 lockdown, but HIV testing and 
ART initiations were heavily impacted. Strategies to increase testing and treatment initiation should be implemented.
Funding Wellcome Trust, Africa Oxford Initiative.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
The number of deaths from COVID-19 continues to rise 
globally, but data quantifying the effect of the pandemic 
on other health conditions are scarce, especially in low-
income and middle-income countries. Interruption of 
supply chains, diversion of resources, and overwhelmed 
health systems could have severe collateral effects 
on existing public health programmes.1–4 Furthermore, 
COVID-19 control measures, such as stay-at-home orders, 
or lockdowns, might limit access to health-care services, 
further jeopardising broader public health goals.3,5,6
In Africa, the impact on HIV services is of particular 
concern. Despite improvement in HIV prevention, testing, 
and treatment, HIV/AIDS remains one of the leading 
causes of mortality, with more than 400 000 deaths on the 
continent in 2019.7 Of the estimated 25·8 million people in 
Africa living with HIV in 2019, 4·3 million were not 
diagnosed, and a further 3·4 million were not receiving 
antiretroviral therapy (ART).7 Modelling studies of dis-
ruptions to HIV programmes by the COVID-19 pandemic 
estimate that interruptions in ART would have the largest 
effect on HIV-related mortality.8,9 In a worst case scenario, 
interruption of ART for 6 months for 50% of patients 
would result in 296 000 excess HIV-related deaths.8
Such scenarios are of particular concern in the 
province of KwaZulu-Natal, in South Africa, which is 
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the country most heavily affected by both COVID-19 
and HIV in Africa. 493 183 cases of COVID-19 had been 
confirmed in South Africa by July 31, 2020,10 and in 
2019 an estimated 7·5 million people were living with 
HIV in the country. An estimated 1·7 million people 
are living with HIV in KwaZulu-Natal, a prevalence 
of 27% in adults aged 15–49 years.11 76 706 cases of 
COVID-19 had been confirmed in KwaZulu-Natal by 
July 31, 2020, making it the third most COVID-19 
affected province in South Africa.10 The largest urban 
area in KwaZulu-Natal is the eThekwini Metropolitan 
Municipality, which has a population of approximately 
3·7 million and includes the city of Durban.12 
South Africa announced a national lockdown on 
March 23, 2020, which was implemented on March 27.6 
Starting at level 5, the lockdown was one of the most 
severe globally, with restrictions on movement and 
cancellation of public transport, although travel to 
receive health care was allowed.6 The lockdown was 
eased to level 4 on May 1, 2020, when public transport 
was allowed,6 and to level 3 on June 1, 2020, which 
allowed some economic activity to resume. 
The impact of lockdown measures in South Africa 
and other African countries on HIV programmes is not 
clear. An interrupted time series analysis13 of data from 
11 rural clinics in South Africa found a 20% increase 
in HIV-related primary care visits after lockdown 
implemen tation. By contrast, two small studies in 
Kenya14,15 described 16–30% decreases in HIV testing 
after lockdown. However, these analyses were from few 
sites and might be biased by long-term trends that were 
not accounted for.
We aimed to quantify the impact of COVID-19 lockdown 
in South Africa on key components of HIV care, namely 
HIV testing, ART initiation, and retention in HIV care, 




We did an interrupted time series analysis of routinely 
collected data from 65 public sector, primary care clinics in 
KwaZulu-Natal, South Africa. We used data from 56 urban 
clinics run by the eThekwini Municipality Health Unit, 
which represents approximately 60% of all public clinics in 
the Metro. We also used data from all nine fixed and 
mobile primary care clinics overseen by Bethesda Hospital, 
a district hospital in the rural uMkhanyakude District in 
northern KwaZulu-Natal. ART is provided free of charge at 
all these clinics, and they remained open during the 
South African national lockdown. Before and throughout 
the lockdown, there were no reports of ART stockouts 
in the study clinics, and public health messaging 
highlighted the importance of ART for all people living 
with HIV.16
Participants 
We included data from people testing for HIV, initiating 
ART, and collecting ART at participating clinics during 
the study period, with no age restrictions. For ART initia-
tions, we excluded patients who were already receiving 
ART and were transferring into care from another clinic. 
For HIV testing, data were available from Jan 1, 2018, to 
July 31, 2020, for all other outcome variables data were 
Research in context
Evidence before this study
The COVID-19 pandemic could greatly affect HIV programmes 
in low-income and middle-income countries. Modelling 
studies have suggested that disruptions to antiretroviral 
therapy (ART) provision would have the worst consequences, 
with a 6-month interruption in treatment for half of people 
who receive ART, leading to nearly 300 000 excess HIV deaths 
in sub-Saharan Africa. However, whether such high levels of 
disruption have occurred is not clear. We searched PubMed 
for the terms (COVID-19 OR SARS-CoV-2) AND (HIV OR AIDS) 
AND (LMIC OR low income country OR middle income 
country OR Asia OR Africa OR Latin America) AND (lockdown 
OR lock-down OR curfew OR impact OR shelter OR restriction) 
from inception until Oct 16, 2020. We found four small 
studies that provided quantitative data comparing HIV care 
outcomes before and after COVID-19 lockdowns. A single site 
cohort study of pre-exposure prophylaxis in 455 pregnant 
women in South Africa found an increase in missed visits 
after lockdown. An interrupted time series analysis from 
11 clinics in rural South Africa found a 20% increase in 
HIV-related primary care visits after lockdown 
implementation, and two studies from Kenya described a 
decrease in numbers of HIV tests in the first month of 
lockdown, compared with the previous 3 months.
Added value of this study
We contribute new evidence of the impact of the COVID-19 
lockdown on HIV care in KwaZulu-Natal, South Africa, which 
has the largest ART programme in the world, and had one of 
the strictest lockdowns in Africa. We analysed a large dataset 
from urban and rural primary care clinics between Jan 1, 2018, 
and July 31, 2020, and used interrupted time series analysis to 
account for longer-term trends. HIV testing and ART 
initiations decreased substantially when lockdown was 
implemented, but ART collection visits decreased only slightly.
Implications of all the available evidence
ART provision was largely maintained during the South African 
lockdown, while HIV testing and ART initiations were more 
heavily affected. After lockdown, and in any future COVID-19 
restrictions, strategies to catch up with HIV testing and increase 
ART initiation should be implemented, alongside efforts to 
maintain treatment provision. 
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available until June 15, 2020. We chose not to use data 
before January, 2018, as earlier trends might have been 
influenced by changes in ART initiation criteria and the 
implementation of universal test and treat in South Africa 
at the end of 2016.
Data sources and data management 
In the South African public sector, data on the number of 
HIV tests done per month at each clinic are routinely 
recorded in the District Health Information System12 and 
reported by gender and age group. For patients initiating 
and receiving ART, data on demographics, clinical status, 
and clinic visits are routinely recorded in an electronic 
register17 that is compared monthly against clinic registers 
and a subset of clinical charts. For this analysis, anonym-
ised patient-level data were analysed and aggregated into 
weekly counts of ART initiations and ART collection 
visits. During the COVID-19 lockdown, clinical staff, data 
capturers, and health information system managers were 
classed as essential workers. This designation meant that 
transport arrange ments were made to enable attendance 
at work, minimising disruptions to data entry and data 
capture.
Outcomes 
The primary outcomes were HIV tests per month, ART 
initiations per week, and ART collection visits per week 
at participating clinics during the study period. The 
number of weekly ART collection visits was a function 
of when visits were scheduled, and whether patients 
attended these scheduled visits. Because visit scheduling 
might also have changed during lockdown, we assessed 
a secondary outcome of missed ART collection visits per 
week. For the missed visits variable, we used the date of 
next scheduled ART collection visit to calculate visits 
that were missed by more than 2 weeks, as defined by 
South African guidelines.18 Patients who attended earlier 
than their next scheduled visit were not defined as 
missing a visit, and we restricted the period of interest 
to end 2 weeks before the last day of data collection, 
because by definition a missed visit required no visit in 
the next 2 weeks. We stratified the outcome data by 
gender and by rural or urban district (according to clinic 
location).
Statistical analysis 
We used descriptive statistics to summarise demographic 
and clinical data, and present crude summaries of out-
comes before and after lockdown. We did not summarise 
HIV testing data by age, because different age categories 
were used for recording during the study period. We did 
interrupted time series segmented regression analyses 
by fitting a Poisson regression model with Newey–West 
standard errors19,20 to account for autocorrelation and 
heteroskedasticity. The model included a time variable, 
a dummy lockdown variable indicating pre-lockdown 
and post-lockdown, and an interaction term between 
time and the lockdown variable. This approach takes 
account of pre-lockdown trends and allows estimation of 
the effect of lockdown at various timepoints by centring 
time at that timepoint. We used the model to estimate 
the immediate impact of lockdown and the effect of the 
lockdown by the end of the study period. We estimated 
the post-lockdown trend for each outcome by adding 
together the coefficients associated with time and the 
time–lockdown interaction. We did analyses for ART 
initiations and ART collection visits by weekly counts, 
but we present trends of these outcomes by monthly 
periods to facilitate comparisons with monthly HIV 
testing trends. We built separate models by gender, 
age, and rural and urban group. To account for seasonal 
changes in clinic activity (eg, holiday periods when 
clinics remain open but visits are typically fewer), we 
did a sensitivity analysis with two pairs of sine and 
cosine terms (Fourier terms) included in the model. 
We also did a sensitivity analysis of trends in positive 
HIV tests. We analysed data using R 4.0 (R Foundation 
for Statistical Computing, Vienna, Austria; appendix).
Ethical approval 
This work was approved by University of Kwazulu-Natal 
Biomedical Research Ethics Committee (BE646/17), 
the KwaZulu-Natal Department of Health’s Provincial 
Health Research Ethics Committee (KZ_201807_021), 
the eThekwini Municipality Health Unit, and the 
Bethesda Hospital Ethics Committee, with a waiver for 
informed consent for analysis of anonymised, routinely 
collected data.
Role of the funding source 
The funders had no role in the study design, data collection, 
analysis, interpretation, or writing of the paper.  
See Online for appendix




Total in study period 1 315 439 71 142 2 319 992 339 474
Median age, years (IQR)§ NA 32 (27–39) 37 (31–45) 36 (30–43)
By age group§
0–14 years NA 891 (1·2%) 48 440 (2·1%) 7112 (2·1%)
15–24 years NA 9734 (13·7%) 135 649 (5·9%) 26 249 (7·7%)
25–49 years NA 55 840 (78·5%) 1 785 187 (76·9%) 265 408 (78·2%)
≥50 years NA 4741 (6·7%) 457 647 (15·1%) 40 705 (12·0%)
Gender
Female 861 265 (65·5%) 46 520 (65·4%) 1 580 202 (68·1%) 224 799 (66·2%)
Male 454 174 (34·5%) 24 622 (34·6%) 739 790 (31·9%) 114 675 (33·8%)
District of clinic
Urban 1 269 811 (96·5%) 68 821 (96·7%) 2 216 761 (95·6%) 311 746 (91·8%)
Rural 45 628 (3·5%) 2321 (3·3%) 103 231 (4·4%) 27 728 (8·2%)
Data are n (%) unless otherwise specified. ART=antiretroviral therapy. *Jan 1, 2018, to July 31, 2020. †Jan 1, 2018, 
to June 15, 2020. ‡Jan 1, 2018, to June 1, 2020. §Age in routine HIV testing data was recorded using varying age 
categories during the study period and is therefore not available. 
Table 1: Demographics of people who had an HIV test, initiated ART, or collected ART at 65 clinics in 
KwaZulu-Natal, South Africa
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Results
Between Jan 1, 2018, and July 31, 2020, 1 315 439 HIV 
tests were done at all participating clinics. Between 
Jan 1, 2018, and June 15, 2020, 71 142 people started 
ART, and 235 719 people attended 2 319 992 ART 
collection visits (median 9 visits per person, IQR 5–14). 
Between Jan 1, 2018, and June 1, 2020, 339 474 ART 
collection visits were missed. Demographic details are 
presented in table 1. 65·4–68·1% of outcomes were 
recorded in women, reflecting the higher prevalence of 
HIV among women in South Africa,11 and 91·8–96·7% 
of outcomes occurred at urban clinics. Pre-lockdown, 
December, 2018 and 2019 had the lowest counts of HIV 
tests, ART initiations, ART collection visits, and missed 
visits (figure).
In the 27 months before the lockdown on March 27, 2020, 
a median of 41 926 HIV tests were done per month 
(IQR 37 838–51 069), compared with 38 911 tests per 
month (32 699–42 756) in the 4 months after lockdown 
(April, 2020–July, 2020). Before lockdown, a median of 
2691 (2425–2906) of these HIV tests were positive per 
month, compared with 1638 per month (1568–1662) after 
lockdown. The median proportion of positive tests was 
6·1% (IQR 5·4–7·0%) before lockdown and 4·3% 
(4·0–4·8%) after lockdown. The Poisson segmented re-
gression analysis showed a 47·6% decrease in HIV 
testing in the first month of lockdown (April, 2020) 
(incidence rate ratio [IRR] 0·524, 95% CI 0·446–0·615; 
figure, table 2). After April, 2020, HIV testing increased 
by a trend of 18·3% per month (IRR 1·183, 95% CI 
1·113–1·256), reaching 82·7% of pre-lockdown levels 
(0·827, 95% CI 0·704–0·972) by July, 2020. Findings were 
similar between women and men (table 2), and in a 
sensitivity analysis of positive HIV tests (appendix p 1). In 
the urban clinics, the decrease in HIV testing at lockdown 
was larger than in the rural clinics (IRR 0·515, 95% CI 
0·436–0·610 in the urban centres vs 0·823, 0·681–0·994 
in the rural centres; table 2).
In the 117 weeks before lockdown, a median of 571 ART 
initiations were done per week (IQR 498–678), compared 
with 375 per week (331–399) in the 11 weeks after 
implemen tation of lockdown. The segmented regression 
analysis showed a 46·2% decrease in ART initiations 
in the first full week of lockdown (March 30, 2020, to 
April 5, 2020; IRR 0·538, 95% CI 0·459 –0·630; figure, 
table 2). Thereafter, ART initiations gradually recovered 
by a trend of 15·6% per month (IRR 1·156, 95% CI 
1·085–1·230; trend presented by month to allow 
comparisons with monthly HIV testing trends), reaching 
75·3% of pre-lockdown levels (IRR 0·753, 95% CI 
Figure: Poisson segmented regression analyses of HIV testing, ART initiations, 
ART collection visits, and missed visits, before and after the COVID-19 
lockdown in 65 clinics in KwaZulu-Natal, South Africa
(A) HIV tests per month. (B) ART initiations per week. (C) ART collection visits 
per week. (D) Missed visits per week. ART=antiretroviral therapy.
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0·637–0·890) by mid-June, 2020. This recovery in ART 
initiations occurred mainly in women (IRR 1·225 per 
month, 95% CI 1·118–1·341), whereas ART initiations 
remained low in men (1·040 per month, 0·957–1·132). 
The effect of lockdown on ART initiations was similar 
across age groups, and rural and urban clinics (table 2).
Patients attended a median of 18 519 ART collection 
visits per week before lockdown (IQR 17 074–19 922), 
compared with 17 863 per week (17 509–18 995) after 
implemen tation of lockdown. The segmented regression 
analysis showed weak evidence of a small decrease in 
the number of ART collection visits in the first 
full week of lockdown (IRR of lockdown effect 0·932, 
95% CI 0·794–1·093; figure, table 2). After lockdown, 
the number of ART collections per month remained 
broadly constant (IRR 0·974, 95% CI 0·900–1·053), but 
by the end of data collection in mid-June, there was 
some evidence to suggest that ART collections visits 
were lower than pre-lockdown levels (IRR 0·859, 95% CI 
0·747–0·989%). Results were similar between men and 
women, age groups, and for rural and urban clinics 
(table 2). In post-hoc analyses, we added an indicator 
term for the 4 weeks between the date of the first 
confirmed case of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) in South Africa and the 
start of the South African lockdown. The number of 
ART collection visits were higher in the 4 weeks between 
SARS-CoV-2 identification and lockdown (IRR 1·233, 
95% CI 1·113–1·366), even when taking seasonality into 
account (1·165, 1·042–1·303). We also found that the 
number of early visits, in which people attended more 
than 7 days before their scheduled visit date, increased 
in this pre-lockdown period (1·271, 1·110–1·456).
Before lockdown, a median of 2637 visits per week 
were missed (IQR 2420–2938), compared with 2714 per 
week after lockdown (2151–3777; figure). The Poisson 
regression model showed a large increase in missed 
visits in the first week of lockdown (IRR 1·926, 95% CI 
1·550–2·394). Thereafter, missed visits decreased rapidly 
as lockdown continued (0·569 per month, 0·432–0·747), 
and returned to pre-lockdown levels by the end of 
May, 2020, when the lockdown moved from level 5 to 
level 4 (1·006, 0·794–1·276; figure). Of the 19 183 people 
who missed a visit by 2 weeks during the level 5 
lockdown period, 11 259 (58·7%) subsequently collected 
within the next month (ie, 42 days after their scheduled 
visit). We did not observe any marked differences in 
results between men and women or in different age 
groups. In the rural clinics, the increase in missed visits 
in the first week of lockdown was much less marked 
(IRR 1·274, 95% CI 1·076–1·509) than in the urban 
clinics (1·991, 1·584–2·503; table 2).
After adding two Fourier terms to account for 
seasonality, our findings were similar to those when 
seasonality was not included (table 3, figure). We also 
did a post-hoc analysis among people referred into 
a community ART delivery programme.21 Community 
Incidence rate ratio 
at lockdown
Incidence rate ratio 
at study end
Pre-lockdown trend* Post-lockdown 
trend*
HIV testing†
Overall 0·524 (0·446–0·615) 0·827 (0·704–0·972) 1·015 (1·009–1·022) 1·183 (1·113–1·256)
Gender
Women 0·563 (0·480–0·661) 0·865 (0·741–1·010) 1·013 (1·007–1·019) 1·169 (1·100–1·247)
Men 0·456 (0·387–0·537) 0·761 (0·638–0·907) 1·020 (1·013–1·028) 1·210 (1·147–1·277)
District
Urban 0·515 (0·436–0·610) 0·827 (0·700–0·978) 1·016 (1·010–1·023) 1·190 (1·115–1·270)
Rural 0·823 (0·681–0·994) 0·785 (0·639–0·965) 0·996 (0·985–1·006) 0·980 (0·922–1·042)
ART initiation‡
Overall 0·538 (0·459–0·630) 0·753 (0·637–0·890) 0·996 (0·991–1·004) 1·156 (1·085–1·230)
Gender
Women 0·495 (0·417–0·588) 0·801 (0·651–0·985) 0·996 (0·987–1·004) 1·225 (1·118–1·341)
Men 0·616 (0·513–0·740) 0·675 (0·571–0·797) 1·000 (0·996–1·009) 1·040 (0·957–1·132)
Age, years
0–14 0·370 (0·153–0·896) 0·544 (0·270–1·096) 0·996 (0·987–1·004) 1·175 (0·640–2·164)
15–24 0·400 (0·334–0·479) 0·772 (0·640–0·932) 1·022 (1·013–1·031) 1·363 (1·256–1·476)
25–49 0·577 (0·492–0·676) 0·739 (0·624–0·876) 0·991 (0·987–1·000) 1·108 (1·040–1·180)
≥50 0·481 (0·399–0·579) 0·796 (0·664–0·953) 0·991 (0·983–1·000) 1·230 (1·161–1·335)
District
Urban 0·536 (0·458–0·628) 0·750 (0·631–0·892) 0·996 (0·991–1·004) 1·156 (1·080–1·230)
Rural 0·588 (0·365–0·947) 0·863 (0·625–1·191) 0·987 (0·983–0·996) 1·166 (0·869–1·560)
ART collection visits‡
Overall 0·932 (0·794–1·093) 0·859 (0·747–0·989) 1·009 (1·000–1·013) 0·974 (0·900–1·053)
Gender
Women 0·916 (0·780–1·075) 0·865 (0·753–0·994) 1·009 (1·000–1·013) 0·983 (0·908–1·062)
Men 0·965 (0·823–1·131) 0·847 (0·733–0·978) 1·009 (1·004–1·013) 0·953 (0·880–1·031)
Age, years
0–14 0·908 (0·790–1·043) 0·780 (0·703–0·866) 1·013 (1·009–1·017) 0·949 (0·888–1·017)
15–24 0·875 (0·766–1·001) 0·851 (0·753–0·960) 1·026 (1·017–1·031) 1·013 (0·957–1·071)
25–49 0·933 (0·796–1·094) 0·865 (0·751–0·995) 1·009 (1·000–1·013) 0·974 (0·900–1·053)
≥50 0·946 (0·787–1·137) 0·836 (0·710–0·984) 1·004 (1·000–1·009) 0·949 (0·861–1·049)
District
Urban 0·926 (0·786–1·090) 0·850 (0·736–0·982) 1·009 (1·004–1·013) 0·970 (0·896–1·053)
Rural 1·065 (0·969–1·171) 1·080 (0·985–1·185) 0·996 (0·991–1·000) 1·000 (0·957–1·044)
Missed ART collection visits‡
Overall 1·926 (1·585–2·341) 0·682 (0·455–1·021) 1·000 (0·996–1·004) 0·569 (0·432–0·747)
Gender
Women 2·045 (1·686–2·481) 0·691 (0·454–1·052) 0·996 (0·991–1·000) 0·555 (0·419–0·734)
Men 1·710 (1·399–2·090) 0·664 (0·457–0·965) 1·000 (0·996–1·004) 0·601 (0·463–0·779)
Age, years
0–14 1·568 (1·325–1·856) 0·555 (0·429–0·717) 1·004 (1·000–1·009) 0·572 (0·472–0·690)
15–24 1·682 (1·413–2·001) 0·554 (0·374–0·820) 1·022 (1·017–1·026) 0·561 (0·430–0·727)
25–49 1·947 (1·594–2·378) 0·685 (0·451–1·042) 1·000 (0·996–1·000) 0·566 (0·428–0·751)
≥50 2·030 (1·665–2·474) 0·782 (0·552–1·109) 0·987 (0·983–0·991) 0·589 (0·463–0·751)
District
Urban 1·991 (1·621–2·446) 0·677 (0·433–1·057) 1·000 (0·996–1·004) 0·555 (0·412–0·751)
Rural 1·274 (1·111–1·460) 0·745 (0·636–0·872) 1·004 (0·996–1·009) 0·751 (0·674–0·834)
Data are incidence rate ratio (95% CI) or trend (95% CI). ART=antiretroviral therapy. *Slope change per month 
†Autocorrelation addressed using Newey–West standard errors to calculate CI, with lag up to 2. ‡Autocorrelation 
addressed using Newey–West standard errors to calculate CI, with lag up to 3. 
Table 2: Poisson segmented regression models of the impact of COVID-19 lockdown on HIV services at 
65 clinics in KwaZulu-Natal, South Africa
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ART collections are not recorded as clinic visits, and so 
difficulties in collecting treatment from community 
pick-up points during lockdown could have led to 
an increase in ART collection visits at study clinics. 
We found no evidence of an increase in study clinic 
collection visits among people referred into the 
community ART delivery programme. The number of 
unscheduled clinic visits in this population decreased 
in the first week of lockdown (IRR 0·732, 95% CI 
0·551–0·974), and was similar to pre-lockdown levels 
by the end of the study period (1·163, 0·973–1·391).
Discussion 
We present data from a large clinic population in 
KwaZulu-Natal, South Africa, that show an almost 
50% decrease in HIV testing and ART initiations at the 
beginning of the COVID-19 lockdown, with a gradual 
improvement over the next 3 months towards pre-
lockdown levels. ART collection visits decreased slightly 
and missed ART collection visits increased for a short 
time. These trends did not differ markedly by age or 
gender, apart from ART initiations, which remained low 
among men but gradually improved among women. 
Overall, the impact of the lockdown tended to be less 
marked in the rural clinics. These findings suggest that 
HIV services were generally maintained for people 
already receiving ART. However, engaging new people 
into care (through HIV testing and subsequent treatment 
initiation) was impeded by the lockdown, particularly in 
urban clinics.
To date, there are few published data from low-income 
and middle-income countries that quantify the effect of 
COVID-19 lockdowns on HIV services and patient-
related outcomes along the HIV care cascade. The 
studies that have been published were small, and unlike 
our analysis, they do not account for long-term trends 
or seasonal variations, which might have influenced 
outcomes. A single-site, pre-exposure prophylaxis study22 
of 455 pregnant women in South Africa reported 
that 34% of patients missed visits before lockdown, 
increasing to 57% after lockdown (odds ratio 2∙36, 
95% CI 1∙73–3∙16). In keeping with our findings, 
two descriptive analyses from small studies in Kenya 
(two sites14 and three sites15) reported that 15–30% fewer 
HIV tests were done in April, 2020, than were done per 
month in January to March, 2020.14,15 National laboratory 
data23 from South Africa comparing the 2 months pre-
lockdown with the first month of lockdown showed 
decreases of 33% in CD4 cell count (usually done at HIV 
diagnosis or ART initiation) and 22% in viral load testing 
(usually done for ART monitoring). However, decreased 
HIV viral load PCR testing could reflect changes in 
laboratory system capacity due to increased SARS-CoV-2 
PCR testing, rather than changes in patient clinic 
attendance and ART provision.
An interrupted time series analysis13 in 11 primary care 
clinics in rural KwaZulu-Natal found no difference in 
the number of overall clinic visits, but did show a 
20% increase in HIV-related visits immediately after 
lockdown implementation. The study did not distinguish 
between HIV testing, ART initiation, or ART collection 
visits, although the authors hypothesise that the increase 
in use of HIV services reflected a rush to collect ART in 
anticipation of further restrictions or drug shortages. 
In our study, we also found that the COVID-19 lockdown 
affected the rural clinics less than clinics in urban areas, 
where lockdown restrictions might have been more 
heavily enforced. Furthermore, some people who had 
migrated to urban areas for work might have moved back 
to rural areas during the lockdown.
Why were HIV testing and ART initiation most affected? 
A qualitative study in rural Uganda,24 and anecdotal reports 
from studies in Kenya,14,15 suggest that drops in testing 
could be due to a paucity of personal protective equipment 
and space for physical distancing in clinics, as well as 
reduced clinic opening times and staff being redeployed 
from HIV testing to COVID-19 response activities.14,24 In 
South Africa, 28 000 HIV community health-care workers 
were diverted from HIV outreach to COVID-19 symptom 
screening,25 which might have led to fewer referrals to 
clinics for HIV testing. People without established patterns 
of engage ment in care and regular clinic attendance 
to collect treatment might also have been less likely to 
overcome the challenges involved in attending clinics 
during lockdown. These include increased costs, transport 
difficulties, the potential need to provide proof of the 
reason for travel, paucity of resources, and fear of con-
tracting SARS-CoV-2 infection at clinics.14,15,24 The decrease 
Incidence rate ratio at 
lockdown
Incidence rate ratio at 
study end
Pre-lockdown trend* Post-lockdown trend*
HIV testing† 0·475 (0·404–0·559) 0·741 (0·631–0·872) 1·018 (1·012–1·023) 1·180 (1·090–1·279)
ART initiation‡ 0·496 (0·411–0·598) 0·798 (0·645–0·987) 1·000 (0·991–1·004) 1·225 (1·113–1·352)
ART collection visits‡ 0·859 (0·733–1·007) 0·852 (0·745–0·975) 1·009 (1·004–1·013) 1·004 (0·924–1·090)
Missed ART collection visits‡ 1·812 (1·494–2·197) 0·693 (0·459–1·048) 1·000 (0·996–1·004) 0·595 (0·451–0·783)
Data are rate (95% CI) or trend (95% CI). ART=antiretroviral therapy. *Slope change per month. †Autocorrelation addressed using Newey–West standard errors to calculate CI, 
with lag up to 2. ‡Autocorrelation addressed using Newey–West standard errors to calculate CI, with lag up to 3. 
Table 3: Sensitivity analyses taking account of seasonality using two Fourier pairs in Poisson segmented regression models of the impact of COVID-19 
lockdown on HIV services in KwaZulu-Natal, South Africa
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in HIV testing, positive HIV tests, and ART initiations 
were broadly similar, suggesting that the decrease in ART 
initiations was largely due to decreased testing, rather than 
additional attrition in the cascade between testing HIV 
positive and initiating ART.
The lockdown did cause some disruption to ART 
collections, with a short increase in missed ART collec tion 
visits in the first month of lockdown. However, collections 
rapidly returned to pre-lockdown levels, and most people 
who missed a visit did attend in the next month, meaning 
that overall ART collection visits did not decrease drastically 
in the study clinics. These findings are similar to findings 
from a survey26 of 301 patients in a community ART 
delivery programme in urban KwaZulu-Natal, of whom 
only 8% reported delaying ART collection during the 
lockdown,26 despite 34% reporting increased travel times 
or costs to collect ART and 51% reporting long waiting 
times to collect treatment.26 ART collection might have 
been prioritised by patients already engaged in HIV 
care and aware of the importance of maintaining high 
adherence. Similar to the results of the study from rural 
KwaZulu-Natal,13 we found a pre-lockdown increase in 
ART collection visits, suggesting that people were stocking 
up in preparation for potential disruptions. Clinics were 
also able to facilitate ART provision through strategies 
such as multi-month prescribing and differentiated service 
delivery programmes.16,27,28 We plan further analyses to 
quantify how these strategies were implemented, as they 
might account for the slight decrease in ART collection 
visits after lockdown. For this analysis, any unmeasured 
increase in multi-month prescribing or community ART 
delivery would bias our results towards larger decreases in 
clinic ART collection visits after lockdown, rather than 
masking a substantial decrease in visits. We also found no 
evidence of an increase in people returning early to study 
clinics instead of collecting in the community ART delivery 
programme during lockdown.
Strengths of our study include the large number of 
routine public sector clinics from both urban and rural 
settings that are likely to reflect aspects of HIV programmes 
across southern and eastern Africa; although South Africa’s 
large ART programme might be better resourced and 
hence more resilient to COVID-19 impacts.29 Our use of 
long-term routine data takes into account underlying 
trends in HIV testing and ART use, and allows more 
accurate quantification of the effect of the COVID-19 lock-
down. However, due to the format of HIV testing data, 
we were not able to assess HIV testing by weekly counts, 
which would have allowed a more detailed assessment of 
shorter-term trends. We were also unable to assess HIV 
viral load outcomes due to the time taken for these results 
to be entered into the records system.
Our findings suggest that, in one of the regions most 
affected by both HIV and COVID-19, the worst modelled 
scenarios of the impact of COVID-19 on HIV are unlikely 
to play out. We did not find evidence of large disruptions 
to ART provision, which is the main driver of morbidity 
and mortality in published models.8 Instead, efforts 
to continue providing treatment to people in the ART 
programme appear to have been largely successful. 
Although this evidence is reassuring, COVID-19-related 
disruptions to ART supply chains and future COVID-19 
outbreaks and lockdowns still pose a threat to HIV 
programmes.30 Furthermore, our findings suggest that 
people who are not yet in HIV care were most affected by 
the lockdown. As countries in Africa consolidate health 
systems after the first wave of COVID-19, and manage 
potential second waves, efforts to catch-up with HIV 
testing and initiation of ART should be prioritised. 
Integrating HIV and SARS-CoV-2 testing programmes 
could be beneficial,31 and WHO and other international 
organisations are now advocating for an increased focus 
on HIV self-testing.28 Innovative strategies to facilitate 
access to treatment are also required, such as home and 
community-based ART initiation.32 Research into HIV 
service provision in other settings, and the factors that 
impeded HIV testing and treatment initiation during the 
COVID-19 lockdown, is needed to inform public health 
responses to future COVID-19 outbreaks.
In conclusion, engagement of people in HIV care in 
South African primary care clinics through HIV testing 
and treatment initiation was severely impacted by the 
COVID-19 lockdown, with a gradual recovery towards 
pre-lockdown levels as restrictions eased. There were 
no large changes in ART collection visits. Strategies to 
increase HIV testing and treatment initiation should be 
implemented to address the current and potential future 
outbreaks.
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